Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05615220 · ClinicalTrials.gov registry record · Phase 3
Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults
A Phase 3 study, sponsored by Emalex Biosciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 216
- Enrollment target
NCT05615220 is a Phase 3 study that has completed, run by Emalex Biosciences. The registered enrollment target is 216 participants.
The verdict
NCT05615220, a Phase 3 study, has completed, sponsored by Emalex Biosciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 216 participants
- Enrollment target
Study Summary
This Phase 3 multicenter study evaluates the maintenance of efficacy, safety and tolerability of ecopipam tablets in children, adolescents and adults in the treatment of Tourette's Disorder (TD). The study includes an open-label period followed by a double-blind, placebo-controlled, randomized withdrawal period.
Interventions
- DRUG Ecopipam Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 216 participants |
| Start Date | 2023-01-31 |
| Est. Completion | 2025-02-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05615220
The ClinicalTrials.gov registry entry for NCT05615220 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 216 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emalex Biosciences, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ecopipam Hydrochloride is the first listed.
NCT05615220 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05615220 about?
NCT05615220 is a clinical study titled "Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults". This Phase 3 multicenter study evaluates the maintenance of efficacy, safety and tolerability of ecopipam tablets in children, adolescents and adults in the treatment of Tourette's Disorder (TD). The study includes an open-label period followed by a double-blind, placebo-controlled, randomized withd...
What is the current status of trial NCT05615220?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 216 participants. The study started on 2023-01-31. Estimated completion is 2025-02-04.
What interventions are being tested in trial NCT05615220?
The interventions under investigation include: Ecopipam Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT05615220?
This trial is sponsored by Emalex Biosciences, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.